Incorporation of biomarker assessment in novel clinical trial designs: Personalizing brain tumor treatments

Evanthia Galanis, Wenting Wu, Jann N Sarkaria, Susan M. Chang, Howard Colman, Daniel Sargent, David A. Reardon

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalCurrent Oncology Reports
Volume13
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

Brain Neoplasms
Biomarkers
Clinical Trials
Molecular Biology
Therapeutics

Keywords

  • Adaptive design
  • Biomarker enrichment design
  • Biomarkers
  • Glioma
  • Marker by treatment interaction design
  • Neurooncology trials

ASJC Scopus subject areas

  • Oncology

Cite this

Incorporation of biomarker assessment in novel clinical trial designs : Personalizing brain tumor treatments. / Galanis, Evanthia; Wu, Wenting; Sarkaria, Jann N; Chang, Susan M.; Colman, Howard; Sargent, Daniel; Reardon, David A.

In: Current Oncology Reports, Vol. 13, No. 1, 02.2011, p. 42-49.

Research output: Contribution to journalArticle

Galanis, Evanthia ; Wu, Wenting ; Sarkaria, Jann N ; Chang, Susan M. ; Colman, Howard ; Sargent, Daniel ; Reardon, David A. / Incorporation of biomarker assessment in novel clinical trial designs : Personalizing brain tumor treatments. In: Current Oncology Reports. 2011 ; Vol. 13, No. 1. pp. 42-49.
@article{a3c62d96f2c04767a0e2c8f408a9a2b5,
title = "Incorporation of biomarker assessment in novel clinical trial designs: Personalizing brain tumor treatments",
abstract = "Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.",
keywords = "Adaptive design, Biomarker enrichment design, Biomarkers, Glioma, Marker by treatment interaction design, Neurooncology trials",
author = "Evanthia Galanis and Wenting Wu and Sarkaria, {Jann N} and Chang, {Susan M.} and Howard Colman and Daniel Sargent and Reardon, {David A.}",
year = "2011",
month = "2",
doi = "10.1007/s11912-010-0144-x",
language = "English (US)",
volume = "13",
pages = "42--49",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Incorporation of biomarker assessment in novel clinical trial designs

T2 - Personalizing brain tumor treatments

AU - Galanis, Evanthia

AU - Wu, Wenting

AU - Sarkaria, Jann N

AU - Chang, Susan M.

AU - Colman, Howard

AU - Sargent, Daniel

AU - Reardon, David A.

PY - 2011/2

Y1 - 2011/2

N2 - Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

AB - Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.

KW - Adaptive design

KW - Biomarker enrichment design

KW - Biomarkers

KW - Glioma

KW - Marker by treatment interaction design

KW - Neurooncology trials

UR - http://www.scopus.com/inward/record.url?scp=79551557586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551557586&partnerID=8YFLogxK

U2 - 10.1007/s11912-010-0144-x

DO - 10.1007/s11912-010-0144-x

M3 - Article

C2 - 21125354

AN - SCOPUS:79551557586

VL - 13

SP - 42

EP - 49

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 1

ER -